Africa imports 99 percent of its vaccines despite consuming a quarter of the global vaccine supply, leaving the region highly vulnerable and dependent on outside doses.
Countries including South Africa and Egypt have already started to produce COVID-19 vaccines, and the Partnerships for African Vaccine Manufacturing has announced a goal for 60 percent of all vaccines used on the continent to be produced by African nations by 2040. Now the question is how to achieve that ambitious target.
This event, hosted by Devex in partnership with Open Society, will explore how the Partnerships for African Vaccine Manufacturing and the G-7’s Pact for Pandemic Readiness can support manufacturing; how Africa’s vaccine manufacturing can be supported through improved financing; and the roles that international donors and agencies must play to better support a thriving pharmaceutical industry on the continent.
Speakers
-
Natalie Donback
Moderator
Natalie Donback is an associate editor and reporter at Devex.
-
Ebere Okereke
Speaker
Ebere Okereke is a senior technical adviser for the Tony Blair Institute for Global Change and an honorary senior public health adviser for the Africa Centers for Disease Control and Prevention (Africa CDC).
-
Petro Terblanche
Speaker
Petro Terblanche is managing director of Afrigen Biologics.
-
L. Muthoni Wanyeki
Speaker
L. Muthoni Wanyeki is the executive director for Open Society–Africa.
Read more
Vaccine Justice
Q&A: Africa’s Fight for Vaccine Equity
As the pandemic enters its third year, African Alliance founder Tian Johnson shares reflections on how to make progress in the push for vaccine equity and what African civil society organizations are asking for now.
explainer
Why Responding to COVID-19 Requires Justice, Not Charity
The development of effective vaccines has been a great achievement in the fight against COVID-19, but true success will not be won unless we fix vaccine shortages around the world and ensure affordable and wide access.
Fighting COVID-19
A $100 Million Booster for Vaccine Equity
As the fight against COVID-19 continues, all countries need access to vaccines, not just the rich ones. Open Society’s $100 million commitment to COVAX will help deploy millions of vaccines to the nations most in need.